Other Acute Pain, Pain Experienced During Cystoscopy
Conditions
Keywords
Intranasal fentanyl, Cystoscopy
Brief summary
The purpose of this study is to assess the safety and efficacy of intranasally-administrated fentanyl pectin spray (Lazanda®)given to decrease the pain during cystoscopy (the passage of a telescopic instrument into the bladder for purpose of diagnosing the cause of blood in the urine, urinary complaints or any other problems with the urinary bladder). The current standard practice is to use Lidocaine jelly (a local anesthetic) given through the urethra to lubricate and decrease local pain. In this study, an additional medicine (Lazanda®) is used to reduce pain that occurs during and after the above procedure.
Detailed description
In this prospective study, twenty subjects will be enrolled. The first ten will receive a dose of 100mcg pectin fentanyl nasal spray (Lazanda®). The second ten will receive a dose of 200mcg pectin fentanyl nasal spray (Lazanda®) if the 100mcg was well tolerated in the first ten. In all cases, Lidocaine jelly is used as an local anesthetic in the urethra.
Interventions
DRUGFentanyl pectin
comparison of Intranasal fentanyl 100mcg vs 200 mcg.
Sponsors
Depomed
Richard C Reznichek, MD
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1\. Male adult patients scheduled for cystoscopy; additional procedures (e.g. ureteral stent placement, stent exchange, bladder biopsy, retrograde pyelogram) may be included.
Exclusion criteria
1. History of analgesic abuse or opioid tolerance 2. Allergy to fentanyl or to any of the components of Lazanda® 3. Acute/chronic nasal problems such as rhinitis or sinusitis 4. Acute bronchial asthma / upper airway obstruction 5. Presence of bradycardia or history of seizures 6. Concomitant use of drugs that inhibit cytochrome P450 isoenzyme 3A4 (e.g., ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, nefazodone, amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, monoamine oxidase inhibitors and verapamil) or exposure to these drugs 30 days prior to placement on the study. 7. Concomitant use of vasoconstrictive nasal decongestants (e.g., oxymetazoline, phenylephrine, xylometazoline) 8. Numeric Rating Scale (NRS) pain score more than 0 at baseline 9. Any situation or condition which, in the investigator's opinion, puts the subject at significant risk, or could confound the study results.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in pain numeric rating scale | within 3 hours post administration of the drug | The primary endpoint is the worst pain experienced at any time during the procedure. Pain will be assessed using the Numeric Rating Scale (NRS score 0 = no pain to 10 = worst possible pain). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Oxyhemoglobin saturation | Every 5 minutes post administration of the drug until 3 hours | Pulse oximetry will be recorded at baseline and every 5 minutes for 3 hours post drug-administration. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Mean arterial blood pressure | every 15 minutes until 3 hours post drug-administration | Will be recorded at baseline and every 15 minutes for 3 hours post drug-administration. |
Countries
United States
Outcome results
None listed